Free Newsletter
Obama takes new tack on healthcare reform
The healthcare reform debate is heating up again as that bipartisan summit meeting of President Obama's nears. And it looks as if the president is using that old "iron fist in a velvet glove" strategy. The velvet glove, of course, would be the calls for bipartisan cooperation, which now extends to the president actually putting forth a comprehensive reform plan designed to help the two parties come to some sort of agreement.
The iron fist? A new resolve to push healthcare legislation through Congress without the famous 60-vote supermajority in the Senate, the number of votes required to get a bill approved without risking filibuster. All along Democrats have thrown around the idea of attaching reform to a budget bill, which can advance on a simple majority. But they never took that approach, partly because they didn't want to be accused of legislative trickery.
That iron fist would only work, however, if enough Democrats are behind this new bill. And the New York Times reports that the Dems in Congress haven't yet seen the president's proposals. So we'll have to wait and see as things develop.
- read the NYT piece
- get more from Bloomberg
- see the article from the Los Angeles Times
ALSO: A firestorm between the Obama administration and health insurers escalated as the Department of Health and Human Services pointed to double-digit price increases or attempted increases in six states to make the case for overhauling the healthcare system. Report
Related Articles:
No reform? Look for more consolidation
What's next for reform-less pharma?
What to cut from growing U.S. healthcare tab?
Dems writing compromise healthcare bill
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: